Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1879-1882

  Jancarikova, D ^a   Pesek, M ^a   Benesova, L ^b   Topolcan, O ^a   Holubec Jr , L ^a   Minarik, Marek ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Laboratory for Molecular Genetics and Oncology   (Czech Republic)

Author keywords

EGFR mutation; Erlotinib; Gefitinib; NSCLC; T790M

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE;

ADULT; BONE METASTASIS; BRAIN METASTASIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; THORACOSCOPY;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34250732736     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Novotny J, Vitek P and Petruzelka L: Non-small cell lung carcinoma. In: Clinical and Radiation Oncology for Clinical Practice. TRITON, pp. 118-128, 2005.
2. Chang AE and Gharib MI: Lung cancer. In: Oncology. An Evidence-based Approach. Springer, NY, USA, pp. 545-622, 2006.
3. Bell DW, Gore I, Okimoto RA, Heymann NG and Sordella R: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics 12: 1315-1316, 2005.
4. Chang AE and Gharib MI: Principles of targeted and biological therapies. In: Oncology. An Evidence-based Approach. Springer, NA, USA, pp. 73-91, 2006.
5. Pao W, Miller VA, Politi KA, Riely GJ et al: Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain, PLoS Medicine, March, pp. 225-237, 2005.
6. Rosell et al: Pharmacogenomics Comes of Age in Selecting Patients for Lung Cancer Treatment, ASCO 2006 Educational book, June 2-6, Atlanta, pp. 425-430, 2006.
7. Clark J, Cools J and Gilliland DG: EGFR Ihibition in Non-small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head, Plos Medicine, March, pp. 195-197, 2006.